PFW Advisors LLC Acquires New Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

PFW Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,990 shares of the company’s stock, valued at approximately $573,000.

A number of other large investors have also bought and sold shares of the company. Sanctuary Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after acquiring an additional 664 shares during the period. Sequoia Financial Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 0.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after purchasing an additional 805 shares during the period. DGS Capital Management LLC boosted its stake in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after purchasing an additional 872 shares during the period. Smithfield Trust Co grew its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares in the last quarter. Finally, Signaturefd LLC increased its position in shares of Teva Pharmaceutical Industries by 16.9% during the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after buying an additional 1,094 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded down $0.52 during trading on Monday, hitting $20.42. 15,174,058 shares of the stock traded hands, compared to its average volume of 9,156,907. The firm’s fifty day moving average is $18.89 and its 200-day moving average is $18.05. The stock has a market cap of $23.13 billion, a price-to-earnings ratio of -24.02, a PEG ratio of 0.99 and a beta of 0.73. Teva Pharmaceutical Industries Limited has a 52 week low of $10.83 and a 52 week high of $22.80. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.88.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.